Expression of c-erbB-2 in breast cancer cell lines as experimental receptor of magnetic nanoparticles

High mortality in breast cancer is associated to a late diagnosis and therapy of the disease. Our research group is working on the development of an innovative technology to promote selective ablation of breast cancer in early stages by the use of high frequency magnetic fields assisted by magnetic nanoparticles. The concept behind the technical proposal is to increase the electrical conductivity of tumoral tissue by the use of bioconjugated 'magnetic nanoparticle-monoclonal antibody'. Is expected that bioconjugated recognizes specific genes on the surface of cancer cells. The aim of this study was to evaluate the expression of the c-erbB-2 gene and c-erbB-2 antigen in breast cancer cells type BT-474, MCF-7 and MDA-MB-231, as previous step to propose the c-erbB-2 protein as receptor of magnetic nanoparticles. The results suggest that the elected breast cancer cell lines show well-differentiated relative expression of the elected gen and antigen, and sems suitable for experimental evaluation of selective targeting by magnetic nanoparticles.